These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27272167)

  • 21. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
    Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
    Baker D; Wilsmore B; Narasimhan S
    Intern Med J; 2016 Jul; 46(7):792-7. PubMed ID: 27040617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    Forslund T; Wettermark B; Hjemdahl P
    Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban.
    Bai Y; Shi XB; Ma CS; Lip GYH
    Am J Cardiol; 2017 Nov; 120(9):1689-1695. PubMed ID: 28844510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Real-world data on novel oral anticoagulants: the added value of registries and observational studies. Focus on apixaban].
    Pelliccia F; Tanzilli G; Schiariti M; Viceconte N; Greco C; Gaudio C
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 3):3S-21S. PubMed ID: 28290558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
    Hess CN; Al-Khatib SM; Granger CB; Lopes R
    Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C; Finsterer J
    Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
    De Haro J; Bleda S; Varela C; Cañibano C; Acin F
    Curr Med Res Opin; 2016 Jun; 32(6):1167-73. PubMed ID: 26949899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
    Pandya E; Bajorek BV
    J Clin Pharm Ther; 2016 Dec; 41(6):667-676. PubMed ID: 27704588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    Clin Drug Investig; 2020 Nov; 40(11):1053-1061. PubMed ID: 32886321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.